Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.

PURPOSE Vascular targeted photodynamic therapy with WST11 (TOOKAD® Soluble) is a form of tissue ablation that may be used therapeutically for localized prostate cancer. To study dosing parameters and associated treatment effects we performed a prospective, multicenter, phase I/II trial of WST11 vascular targeted photodynamic therapy of prostate cancer. MATERIALS AND METHODS A total of 30 men with unilateral, low volume, Gleason 3 + 3 prostate cancer were enrolled at 5 centers after local institutional review board approval. Light energy, fiber number and WST11 dose were escalated to identify optimal dosing parameters for vascular targeted photodynamic therapy hemi-ablation. Men were treated with photodynamic therapy and evaluated by posttreatment magnetic resonance imaging and biopsy. Prostate specific antigen, light dose index (defined as fiber length/desired treatment volume), toxicity and quality of life parameters were recorded. RESULTS After dose escalation 21 men received optimized dosing of 4 mg/kg WST11 at 200 J energy. On posttreatment biopsy residual prostate cancer was found in the treated lobe in 10 men, the untreated lobe in 4 and both lobes in 1. At a light dose index of 1 or greater with optimal dosing in 15 men 73.3% had a negative biopsy in the treated lobe. Six men undergoing retreatment with the optimal dose and a light dose index of 1 or greater had a negative posttreatment biopsy. Minimal effects were observed on urinary and sexual function, and overall quality of life. CONCLUSIONS Hemi-ablation of the prostate with WST11 vascular targeted photodynamic therapy was well tolerated and resulted in a negative biopsy in the treated lobe in the majority of men. Dosing parameters and the light dose index appear related to tissue response as determined by magnetic resonance imaging and biopsy. These parameters may serve as the basis for further prospective studies.

[1]  E. Barret,et al.  Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. , 2011, International braz j urol : official journal of the Brazilian Society of Urology.

[2]  C. Stief,et al.  Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure , 2015, World Journal of Urology.

[3]  Boris Rubinsky,et al.  Irreversible Electroporation: Implications for Prostate Ablation , 2007, Technology in cancer research & treatment.

[4]  Aytekin Oto,et al.  MR imaging-guided focal laser ablation for prostate cancer: phase I trial. , 2013, Radiology.

[5]  Robert A Weersink,et al.  Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. , 2007, Radiology.

[6]  Robert A Weersink,et al.  Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer , 2009, Physics in medicine and biology.

[7]  Osamu Ukimura,et al.  Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. , 2012, European urology.

[8]  Samir S Taneja,et al.  Candidate selection for prostate cancer focal therapy. , 2010, Journal of endourology.

[9]  T. Wilt,et al.  Can we deliver randomized trials of focal therapy in prostate cancer? , 2014, Nature Reviews Clinical Oncology.

[10]  P. Scardino,et al.  Partial Gland Ablation for Prostate Cancer: Report of a Food and Drug Administration, American Urological Association, and Society of Urologic Oncology Public Workshop. , 2016, Urology.

[11]  S. Taneja,et al.  Can contemporary transrectal prostate biopsy accurately select candidates for hemi‐ablative focal therapy of prostate cancer? , 2009, BJU international.

[12]  P. Validire,et al.  Morbidity of focal therapy in the treatment of localized prostate cancer. , 2013, European urology.

[13]  H. Ahmed,et al.  Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study , 2012, The Lancet. Oncology.

[14]  Avigdor Scherz,et al.  Photocatalytic generation of oxygen radicals by the water-soluble bacteriochlorophyll derivative WST11, noncovalently bound to serum albumin. , 2009, The journal of physical chemistry. A.

[15]  A. Evans,et al.  Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. , 2007, The Journal of urology.

[16]  J. Trachtenberg,et al.  Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11‐vascular‐targeted photodynamic (VTP) therapy , 2015, BJU international.

[17]  H. Ahmed,et al.  Focal cryotherapy of localized prostate cancer: a systematic review of the literature , 2014, Expert review of anticancer therapy.

[18]  A. Scherz,et al.  Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostate. , 2011, The Journal of urology.

[19]  R. Weersink,et al.  Dynamic contrast enhanced MRI as a predictor of vascular-targeted photodynamic focal ablation therapy outcome in prostate cancer post-failed external beam radiation therapy. , 2014, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[20]  O. Cussenot,et al.  Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers , 2015, World Journal of Urology.

[21]  Avigdor Scherz,et al.  WST11, A Novel Water-soluble Bacteriochlorophyll Derivative; Cellular Uptake, Pharmacokinetics, Biodistribution and Vascular-targeted Photodynamic Activity Using Melanoma Tumors as a Model¶ , 2005, Photochemistry and Photobiology.

[22]  J. Rewcastle,et al.  Focal prostate cryoablation: initial results show cancer control and potency preservation. , 2006, Journal of endourology.

[23]  Vyacheslav Kalchenko,et al.  Permanent Occlusion of Feeding Arteries and Draining Veins in Solid Mouse Tumors by Vascular Targeted Photodynamic Therapy (VTP) with Tookad , 2010, PloS one.

[24]  Ian A. Donaldson,et al.  Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting , 2015, European urology.

[25]  A. Villers,et al.  Efficiency of 5-ALA mediated photodynamic therapy on hypoxic prostate cancer: a preclinical study on the Dunning R3327-AT2 rat tumor model. , 2013, Photodiagnosis and photodynamic therapy.

[26]  Andrew B Rosenkrantz,et al.  Role of MRI in minimally invasive focal ablative therapy for prostate cancer. , 2011, AJR. American journal of roentgenology.

[27]  Clare Allen,et al.  TOOKAD® Soluble vascular‐targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer , 2013, BJU international.

[28]  Hashim U. Ahmed,et al.  Photodynamic therapy for focal ablation of the prostate , 2010, World Journal of Urology.

[29]  I. Hsu,et al.  Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. , 2013, International journal of radiation oncology, biology, physics.